Kymriah to Get 4.3% Reduction, Trelegy 0.5% Cut in 1st CEA-Based Price Tweak

A key reimbursement policy panel on April 14 gave the go-ahead to the first cases of price adjustments under the cost-effectiveness assessment (CEA) scheme, with Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) and GlaxoSmithKline’s COPD drug Trelegy (fluticasone furoate + umeclidinium...read more